Cargando…
Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study
BACKGROUND AND OBJECTIVES: Current clinical guidelines recommend thromboprophylaxis for adults hospitalized with coronavirus disease 2019 (COVID‐19), yet it is unknown whether higher doses of thromboprophylaxis offer benefits beyond standard doses. METHODS: We studied electronic health records from...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287673/ https://www.ncbi.nlm.nih.gov/pubmed/35859579 http://dx.doi.org/10.1002/rth2.12753 |
_version_ | 1784748298920263680 |
---|---|
author | Andersen, Kathleen M. Joseph, Corey S. Mehta, Hemalkumar B. Streiff, Michael B. Betz, Joshua F. Bollinger, Robert C. Fisher, Arielle M. Gupta, Amita LeMaistre, Charles F. Robinson, Matthew L. Xu, Yanxun Ng, Derek K. Alexander, G. Caleb Garibaldi, Brian T. |
author_facet | Andersen, Kathleen M. Joseph, Corey S. Mehta, Hemalkumar B. Streiff, Michael B. Betz, Joshua F. Bollinger, Robert C. Fisher, Arielle M. Gupta, Amita LeMaistre, Charles F. Robinson, Matthew L. Xu, Yanxun Ng, Derek K. Alexander, G. Caleb Garibaldi, Brian T. |
author_sort | Andersen, Kathleen M. |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Current clinical guidelines recommend thromboprophylaxis for adults hospitalized with coronavirus disease 2019 (COVID‐19), yet it is unknown whether higher doses of thromboprophylaxis offer benefits beyond standard doses. METHODS: We studied electronic health records from 50 091 adults hospitalized with COVID‐19 in the United States between February 2020 and February 2021. We compared standard (enoxaparin 30 or 40 mg/day, fondaparinux 2.5 mg, or heparin 5000 units twice or thrice per day) versus intermediate (enoxaparin 30 or 40 mg twice daily, or up to 1.2 mg/kg of body weight daily, heparin 7500 units thrice per day or heparin 10 000 units twice or thrice per day) thromboprophylaxis. We separately examined risk of escalation to therapeutic anticoagulation, severe disease (first occurrence of high‐flow nasal cannula, noninvasive positive pressure ventilation or invasive mechanical ventilation), and death. To summarize risk, we present hazard ratios (HRs) with 95% confidence intervals (CIs) using adjusted time‐dependent Cox proportional hazards regression models. RESULTS: People whose first dose was high intensity were younger, more often obese, and had greater oxygen support requirements. Intermediate dose thromboprophylaxis was associated with increased risk of therapeutic anticoagulation (HR, 3.39; 95% CI, 3.22‐3.57), severe disease (HR, 1.22; 95% CI, 1.17‐1.28), and death (HR, 1.37; 95% CI, 1.21‐1.55). Increased risks associated with intermediate‐dose thromboprophylaxis persisted in subgroup and sensitivity analyses varying populations and definitions of exposures, outcomes, and covariates. CONCLUSIONS: Our findings do not support routine use of intermediate‐dose thromboprophylaxis to prevent clinical worsening, severe disease, or death among adults hospitalized with COVID‐19. |
format | Online Article Text |
id | pubmed-9287673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92876732022-07-19 Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study Andersen, Kathleen M. Joseph, Corey S. Mehta, Hemalkumar B. Streiff, Michael B. Betz, Joshua F. Bollinger, Robert C. Fisher, Arielle M. Gupta, Amita LeMaistre, Charles F. Robinson, Matthew L. Xu, Yanxun Ng, Derek K. Alexander, G. Caleb Garibaldi, Brian T. Res Pract Thromb Haemost Original Articles BACKGROUND AND OBJECTIVES: Current clinical guidelines recommend thromboprophylaxis for adults hospitalized with coronavirus disease 2019 (COVID‐19), yet it is unknown whether higher doses of thromboprophylaxis offer benefits beyond standard doses. METHODS: We studied electronic health records from 50 091 adults hospitalized with COVID‐19 in the United States between February 2020 and February 2021. We compared standard (enoxaparin 30 or 40 mg/day, fondaparinux 2.5 mg, or heparin 5000 units twice or thrice per day) versus intermediate (enoxaparin 30 or 40 mg twice daily, or up to 1.2 mg/kg of body weight daily, heparin 7500 units thrice per day or heparin 10 000 units twice or thrice per day) thromboprophylaxis. We separately examined risk of escalation to therapeutic anticoagulation, severe disease (first occurrence of high‐flow nasal cannula, noninvasive positive pressure ventilation or invasive mechanical ventilation), and death. To summarize risk, we present hazard ratios (HRs) with 95% confidence intervals (CIs) using adjusted time‐dependent Cox proportional hazards regression models. RESULTS: People whose first dose was high intensity were younger, more often obese, and had greater oxygen support requirements. Intermediate dose thromboprophylaxis was associated with increased risk of therapeutic anticoagulation (HR, 3.39; 95% CI, 3.22‐3.57), severe disease (HR, 1.22; 95% CI, 1.17‐1.28), and death (HR, 1.37; 95% CI, 1.21‐1.55). Increased risks associated with intermediate‐dose thromboprophylaxis persisted in subgroup and sensitivity analyses varying populations and definitions of exposures, outcomes, and covariates. CONCLUSIONS: Our findings do not support routine use of intermediate‐dose thromboprophylaxis to prevent clinical worsening, severe disease, or death among adults hospitalized with COVID‐19. John Wiley and Sons Inc. 2022-07-15 /pmc/articles/PMC9287673/ /pubmed/35859579 http://dx.doi.org/10.1002/rth2.12753 Text en © 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Andersen, Kathleen M. Joseph, Corey S. Mehta, Hemalkumar B. Streiff, Michael B. Betz, Joshua F. Bollinger, Robert C. Fisher, Arielle M. Gupta, Amita LeMaistre, Charles F. Robinson, Matthew L. Xu, Yanxun Ng, Derek K. Alexander, G. Caleb Garibaldi, Brian T. Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study |
title | Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study |
title_full | Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study |
title_fullStr | Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study |
title_full_unstemmed | Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study |
title_short | Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study |
title_sort | thromboprophylaxis in people hospitalized with covid‐19: assessing intermediate or standard doses in a retrospective cohort study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287673/ https://www.ncbi.nlm.nih.gov/pubmed/35859579 http://dx.doi.org/10.1002/rth2.12753 |
work_keys_str_mv | AT andersenkathleenm thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT josephcoreys thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT mehtahemalkumarb thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT streiffmichaelb thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT betzjoshuaf thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT bollingerrobertc thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT fisherariellem thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT guptaamita thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT lemaistrecharlesf thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT robinsonmatthewl thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT xuyanxun thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT ngderekk thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT alexandergcaleb thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy AT garibaldibriant thromboprophylaxisinpeoplehospitalizedwithcovid19assessingintermediateorstandarddosesinaretrospectivecohortstudy |